EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase mutations are a well-established driver of proliferation in non-small cell lung cancer (NSCLC) and are present in approximately 15% of patients with lung adenocarcinoma in the United States, albeit with greater frequency in women and nonsmokers.